Ling Zeng - 15 Sep 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Chief Legal Officer & Sec'y
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Sep 2021
Net transactions value: -$28,641
Form type: 4
Filing time: 17 Sep 2021, 18:48:17 UTC
Next filing: 17 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise		+4,556			4,556	15 Sep 2021	Direct	F1
transaction	DRNA	Common Stock	Sale	$28,641	-1,334	-29%	$21.47	3,222	17 Sep 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Restricted Stock Units	Options Exercise	$0	-4,556	-25%	$0.000000	13,669	15 Sep 2021	Common Stock	4,556		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSUs and does not represent a discretionary trade by the Reporting Person.
F3	Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of September 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date